Stock listing

LSE:0JQ2 Kala Bio, Inc. Share Price

UK listing (LSE) of Kala Bio, Inc. · home listing NASDAQ:KALA

Follow Kala Bio, Inc. into a list and get an email when it puts out news.

Share price · LSE:0JQ2

$0.178 USD -0.008 (-4.2%)

Close on Oct 27, 2026

Day range
$0.176 – $0.186 USDOct 27, 2026
Volume
1,121 sharesOct 27, 2026
Kala Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KALA · Home$0.166 USD-0.010 (-5.5%)239,704$0.175$0.183$0.163$0.175Close on Oct 30, 2026
LSE:0JQ2$0.178 USD-0.008 (-4.2%)1,121$0.182$0.186$0.176$0.185Close on Oct 27, 2026
Ticker
LSE:0JQ2
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LSE
Currency
USD

What changed lately

Calls

Replays

  • KALA BIO (NASDAQ:KALA) Q2 2022 Earnings Call

    Thu, Aug 11, 2022 · 8:00 AM ET

    Watch Transcript

  • KALA BIO (NASDAQ:KALA) Q1 2022 Earnings Call

    Mon, May 16, 2022 · 8:00 AM ET

    Watch Transcript

  • KALA BIO (NASDAQ:KALA) Q4 2021 Earnings Call

    Tue, Mar 29, 2022 · 8:00 AM ET

    Watch Transcript

Latest news

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

Sep 29, 2026

KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

Sep 17, 2026

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Sep 3, 2026

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Sep 1, 2026

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

Jun 29, 2026

KALA BIO Announces Reverse Stock Split

May 7, 2026

Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments

Apr 28, 2026

Issued by another party

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

Apr 21, 2026

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

Apr 1, 2026

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

Mar 30, 2026

All Kala Bio, Inc. news

Kala Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 114 in all · newest Sep 29, 2026 · oldest 2019
Calls
7 calls with a replay · 7 with a transcript · latest Aug 11, 2022

Where Kala Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KALA · Home listingNASDAQUnited StatesUSD
gettex:27F0gettexGermanyEUR
LS Exchange:A3DWPSLS ExchangeGermanyEUR
BOATS:KALABOATSUnited StatesUSD
LSE:0JQ2 · This pageLSEUnited KingdomUSD
Lang & Schwarz:A3DWPSLang & SchwarzGermanyEUR
Tradegate:27FTradegateGermanyEUR
gettex:27FgettexGermanyEUR
Munich:27FMunichGermanyEUR
LS Exchange:A4243TLS ExchangeGermanyEUR
Frankfurt:27FFrankfurtGermanyEUR
Lang & Schwarz:A4243TLang & SchwarzGermanyEUR

Log in to ask 6ix AI your own questions about Kala Bio, Inc.